: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
To evaluate the pharmacokinetics of thromboprophylactic doses of LMWH enoxaparin in postoperative CABG patients, drug is administered either as a continuous intravenous infusion (CIV) or subcutaneous bolus (SCB) once per 72h. Plasma anti-Xa values are measured 12-14 times during study period and concentration maximums calculated to enable comparison of anti-Xa values between administration routes.
Epistemonikos ID: 70709100722e85510d00d3a43ea84a2527b92ed2
First added on: May 12, 2024